Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) EVP Sells 13,135 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 13,135 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the completion of the transaction, the executive vice president now owns 154,171 shares of the company’s stock, valued at $7,088,782.58. This trade represents a 7.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Tempus AI Stock Performance

TEM traded up $2.29 during midday trading on Wednesday, reaching $48.03. The company’s stock had a trading volume of 11,624,616 shares, compared to its average volume of 5,018,008. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The stock’s 50-day moving average is $55.86 and its 200-day moving average is $51.48.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the third quarter worth $30,000. Operose Advisors LLC bought a new stake in Tempus AI in the 4th quarter worth about $25,000. Farther Finance Advisors LLC purchased a new position in Tempus AI in the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC raised its position in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Tempus AI in the 4th quarter worth about $49,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TEM shares. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Morgan Stanley upped their price target on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. TD Cowen restated a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Needham & Company LLC upped their price target on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Finally, Piper Sandler cut their price target on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.